Short Interest in Barinthus Biotherapeutics plc (NASDAQ:BRNS) Increases By 39.3%

Barinthus Biotherapeutics plc (NASDAQ:BRNS) saw a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 11,700 shares, a growth of 39.3% from the October 31st total of 8,400 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily volume of 45,300 shares, the short-interest ratio is presently 0.3 days.

Barinthus Biotherapeutics Stock Up 3.2 %

Shares of NASDAQ:BRNS traded up $0.03 during trading on Friday, reaching $0.99. 132,073 shares of the company’s stock traded hands, compared to its average volume of 28,846. Barinthus Biotherapeutics has a fifty-two week low of $0.81 and a fifty-two week high of $4.16. The firm has a market cap of $38.98 million, a PE ratio of -0.66 and a beta of -0.59. The company has a 50-day simple moving average of $1.23 and a 200-day simple moving average of $1.44.

Barinthus Biotherapeutics (NASDAQ:BRNS) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.23. The company had revenue of $14.97 million during the quarter. During the same quarter in the previous year, the company earned ($0.37) earnings per share. On average, equities research analysts forecast that Barinthus Biotherapeutics will post -1.52 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently commented on BRNS. Alliance Global Partners dropped their target price on Barinthus Biotherapeutics from $11.00 to $9.50 and set a “buy” rating on the stock in a research report on Tuesday, August 13th. HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of Barinthus Biotherapeutics in a research report on Tuesday, November 19th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Catalina Capital Group LLC purchased a new position in Barinthus Biotherapeutics in the 2nd quarter valued at about $25,000. Ipswich Investment Management Co. Inc. purchased a new position in Barinthus Biotherapeutics in the 2nd quarter worth approximately $32,000. Alphabet Inc. purchased a new position in Barinthus Biotherapeutics in the 2nd quarter worth approximately $2,119,000. Finally, M&G Plc purchased a new position in Barinthus Biotherapeutics in the 2nd quarter worth approximately $7,276,000. 25.20% of the stock is owned by hedge funds and other institutional investors.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.